Literature DB >> 16283207

[Transdermal buprenorphine during pregnancy].

E Ebner1, M Wiedmann.   

Abstract

Buprenorphine has been widely used and studied for over 20 years and has been shown to be an effective opioid analgesic. Some years ago a buprenorphine formulation for transdermal therapy of chronic cancer-related and non-cancer-related pain became available. We report the case of a woman who received a lower dosed transdermal buprenorphine patch (3/5 of a 35 microg/h patch corresponding to release of 21 microg/h buprenorphine) during pregnancy without any complication for herself or the child. The patient has now being using the transdermal system for more than 2 years and has reported continuous excellent pain relief. The buprenorphine patch was well tolerated and produced no effect on vigilance over the whole period of administration.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16283207     DOI: 10.1007/s00482-005-0445-4

Source DB:  PubMed          Journal:  Schmerz        ISSN: 0932-433X            Impact factor:   1.107


  6 in total

1.  Transplacental transfer and metabolism of buprenorphine.

Authors:  Tatiana Nanovskaya; Sujal Deshmukh; Monica Brooks; Mahmoud S Ahmed
Journal:  J Pharmacol Exp Ther       Date:  2002-01       Impact factor: 4.030

2.  Buprenorphine: a safe method for detoxifying pregnant heroin addicts and their unborn.

Authors:  Virginia G Comer; William J Annitto
Journal:  Am J Addict       Date:  2004 May-Jun

3.  High dose buprenorphine in pregnancy.

Authors:  David Ross
Journal:  Aust N Z J Obstet Gynaecol       Date:  2004-02       Impact factor: 2.100

4.  [Opiate addiction in gravidity - consequences for the newborn. Results of an interdisciplinary treatment concept].

Authors:  K Rohrmeister; G Bernert; M Langer; G Fischer; M Weninger; A Pollak
Journal:  Z Geburtshilfe Neonatol       Date:  2001 Nov-Dec       Impact factor: 0.685

5.  Treatment of opioid-dependent pregnant women with buprenorphine.

Authors:  G Fischer; R E Johnson; H Eder; R Jagsch; A Peternell; M Weninger; M Langer; H N Aschauer
Journal:  Addiction       Date:  2000-02       Impact factor: 6.526

6.  [Buprenorphine in pregnancy].

Authors:  H Eder; I Rupp; A Peternell; G Fischer
Journal:  Psychiatr Prax       Date:  2001-09
  6 in total
  2 in total

1.  Oligodendrocyte responses to buprenorphine uncover novel and opposing roles of μ-opioid- and nociceptin/orphanin FQ receptors in cell development: implications for drug addiction treatment during pregnancy.

Authors:  Andrew C Eschenroeder; Allison A Vestal-Laborde; Emilse S Sanchez; Susan E Robinson; Carmen Sato-Bigbee
Journal:  Glia       Date:  2011-10-14       Impact factor: 7.452

2.  Opioid addiction and pregnancy: perinatal exposure to buprenorphine affects myelination in the developing brain.

Authors:  Emilse S Sanchez; John W Bigbee; Wambura Fobbs; Susan E Robinson; Carmen Sato-Bigbee
Journal:  Glia       Date:  2008-07       Impact factor: 7.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.